In the present case, we selected SOX plus trastuzumab therapy as the primary treatment because trastuzumab with cisplatin plus capecitabine or S-1 is the recommended regimen according to several phase II studies in HER-2-positive advanced gastric cancer [7–9]. This evidence concerns the gene ERBB2 and gastric cancer.